Egis Gyogyszergyar Rt.

Basf Aktiengesellschaft

Egyt Gyogyszervegyeszeti Gyar

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Gis Gyogyszergyar Rt.

Egis Cyogyszergvar

Pal Vago

Gyula Simig

Jozsef Reiter

Anna Bakonyi

Imre Moravcsik

Marton Fekete

Istvan Gyertyan

Ferenc Andrasi

Gyula Sebestyen

Tamas Hamori

Pal Berzsenyi

Frigyes Gorgenyi

Gabor Zolyomi

Istvan Simonyi

Eszter Szentkuti

Marta Kovacs

Katalin Horvath

Gyorgyne Mate

Edit Horvath

Istvan Seres

Maria Szeli

Gabor Gigler

Istvan Gacsalyi

Gabor Blasko

Kalman Nagy

Ferenc Lorant Bartha

Janos Fischer

Andras Egyed

Janos Egri

Gyorgy Somogyi

Laszlo Rozsa

Andras Bilkei-Gorzo

Gabor Fazekas

Karoly Tihanyi

Judit Bajnogel

Gyoergy Clementis

Gizella Miholics

Norbert Nemeth

Sandorne Tapai

Klara Daroczi Kazone

Gizelle Miholics

Hilda Botka

Peter Korosi

Egri Janos

Cecilia Salamon Haskane

Peter Toempe

Peter Tömpe

Gyōrgyi Vereczkeyne Donath

Jeno Korosi, Deceased

Peter Botka, Deceased

Erszebet Birkas

Gyōrgy Clementis

The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and isolating the thus obtained rosuvastatin zinc salt (2:1). 

Rosuvastatin zinc salt

The invention refers to a novel process for the preparation of {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetic acid, which comprises hydrolyzing an N,N-disubstituted {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetamide, wherein said substituents are selected from alkyl groups having 1 to 4 carbon atoms optionally substituted by a phenyl group, alkenyl groups having 2 to 4 carbon atoms or cyclohexyl groups, or the substituents together with the adjacent nitrogen atom of the acetoamido group, form a morpholino group.

Process for the preparation of {2-[4-&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy} acetic acid and novel intermediates therefor

The invention relates to new 1-[2-(substituted vinyl)]-3,4-dihydro-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof and pharmaceutical compositions comprising them. The new 1-[2-(substituted vinyl)]-3,4-dihidro-5H-2,3-benzodiazepine derivatives according to the invention correspond to the general formula (I), ##STR1## wherein the variables are hereinbelow defined: The new compounds according to the invention affect the central nervous system and can be used to advantage in the therapy.

1-[2-(substituted vinyl)]-3,4-dihydro-4-dihydro-5H-2,3-benzodiazepine

This invention relates to new 1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said benzodiazepine derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The compounds according to the invention correspond to the general formula (I), ##STR1## wherein the variables are herein below defined, and the compounds possess central nervous activities.

1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives

The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails. The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.

Pharmaceutical composition comprising an organic zinc complex and a

The invention relates to a novel process for the preparation of 1-[3-mercapto-(2S)-methylpropionyl]-pyrrolidine-(2S)-carboxylic acid through the N-acylation of L-proline. According to the process of the invention L-proline is acylated with a 3-halogen-2-methylpropionyl chloride of the formula III ##STR1## wherein Hal is a halogen atom, preferably chlorine or bromine, the obtained 1-[3-halogen-(2S)-methylpropionyl]-pyrrolidine-(2S)-carboxylic acid, wherein Hal is as stated above, is reacted with an alkali thiosulfate or alkali trithiocarbonate and the reaction product is hydrolized with an acid. The process of the invention is very economical as compared with the known processes. The desired product is prepared from methacrylic acid in 4 reaction steps with a total yield of 25 percent and from L-proline in 2 reaction steps with a total yield of 30 percent.

Process for the preparation of

Growing community of inventors

Budapest, Hungary

Pal Vago